Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine
Pharmaceutical Technology
OCTOBER 28, 2022
The vaccine demonstrated a similar safety profile to Pfizer’s marketed 20-serotype shot Prevnar 20 at all assessed doses, and showed non-inferior efficacy. There, the business plans to submit an IND application for a Phase I/II in the second half of 2023, with a readout in 2024. Competition in an increasingly heated market.
Let's personalize your content